Aims. The Seeds Of Life In Space IRAM/NOEMA large program aims at studying a set of crucial complex organic molecules in a sample of sources with a well-known physical structure that covers the various phases of solar-type star formation. One representative object of the transition from the prestellar core to the protostar phases has been observed toward the very low luminosity object (VeLLO) L1521F. This type of source is important to study to link prestellar cores and Class 0 sources and also to constrain the chemical evolution during the process of star formation. Methods. Two frequency windows (81.6-82.6 GHz and 96.65-97.65 GHz) were used to observe the emission from several complex organics toward the L1521F VeLLO. These setups cover transitions of ketene (HCCO), propyne (CHCCH), formamide (NHCHO), methoxy (CHO), methanol (CHOH), dimethyl ether (CHOCH), and methyl formate (HCOOCH). Results. Only two transitions of methanol (A, E) have been detected in the narrow window centered at 96.7 GHz (with an upper limit on E) in a very compact emission blob (∼7″ corresponding to ∼1000 au) toward the northeast of the L1521F protostar. The CS 2-1 transition is also detected within theWideX bandwidth. Consistently with what has been found in prestellar cores, the methanol emission appears ∼1000 au away from the dust peak. The location of the methanol blob coincides with one of the filaments that have previously been reported in the literature. The excitation temperature of the gas inferred from methanol is (10 ± 2) K, while the H gas density (estimated from the detected CS 2-1 emission and previous CS 5-4 ALMA observations) is a factor >25 higher than the density in the surrounding environment (n(H) ≥ 10 cm). Conclusions. Based on its compactness, low excitation temperature, and high gas density, we suggest that the methanol emission detected with NOEMA is (i) either a cold and dense shock-induced blob that formed recently (≤ a few hundred years) by infalling gas or (ii) a cold and dense fragment that may just have been formed as a result of the intense gas dynamics within the L1521F VeLLO system. ; With funding from the Spanish government through the "María de Maeztu Unit of Excellence" accreditation (MDM-2017-0737)
Idiopathic inflammatory myopathies (IIMs) encompass a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and inflammation, but in antisynthetase syndrome arthritis and interstitial lung disease are more frequent and often inaugurate the disease. Clinical practice guidelines (CPGs) have been proposed for IIMs, but they are sparse and heterogeneous. This work aimed at identifying: i) current available CPGs for IIMs, ii) patients ' and clinicians' unmet needs not covered by CPGs. It has been performed in the framework of the European Reference Network on rare and complex connective tissue and musculoskeletal diseases (ReCONNET), a network of centre of expertise and patients funded by the European Union's Health Programme. Fourteen original CPGs were identified, notably recommending that: i) extra-muscular involvements should be assessed; ii) corticosteroids and methotrexate or azathioprine are first-line therapies of IIMs. ii) IVIG is a treatment of resistant-DM that may be also used in other resistant-IIMs; iii) physical therapy and sun protection (in DM patients) are part of the treatment; v) tumour screening for patients with DM include imaging of chest, abdomen, pelvis and breast (in woman) along with colonoscopy (in patients over 50 years); vi) disease activity and damages should be monitor using standardised and validated tools. Yet, only half of these CPGs were evidence-based. Crucial unmet needs were identified both by patients and clinicians. In particular, there was a lack of large multidisciplinary working group and of patients ' preferences. The following fields were not or inappropriately targeted: diagnosis; management of extra-muscular involvements other than skin; co-morbidities and severe manifestations. ; info:eu-repo/semantics/publishedVersion